Competing interests
M.S. received consultation fees and honoraria from BMS. B.K. received grants/research support from Roche, Morphosys, MSD and Hexal, and honoraria from Roche. U.T.H. received grants/research support from Celgene and Roche, and honoraria from Roche, Servier, Novartis and Merck Serono. G.H. received consultation fees from Roche and AstraZeneca, and honoraria from Roche, Amgen, Pierre-Fabre, AstraZeneca, Alexion, Servier, Octapharma, Abbvie, GSK and Beigene. L.W. received honoraria from Roche and Servier and travel support from Amgen. M.B. received consultation fees from Roche, Incyte, Bayer, MSD and Ipsen. A.S. received grants/research support from Bayer, BMS, Chugai and Incyte, and consultation fees/honoraria from Aignostics, Amgen, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seattle Genetics, Takeda and Thermo Fisher. T.B. has worked as a study oncologist for the CUPISCO trial, which is sponsored by Roche and has received reimbursement for study-related travels as well as remuneration for his work as a study oncologist for the benefit of his employer. A.K. received consultation fees and honoraria from Roche and grants/research support from BMS and Molecular Health. All remaining authors declare no competing interests.